Clinical trials
Immune Tolerance clinical trials
Below are recruiting immune tolerance clinical trials, each written for real people, not researchers. We’re tracking 21 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07269041RecruitingPhase 1/Phase 2
Immune tolerance after liver transplant
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
Los Angeles, CaliforniaAges 18 years+ - NCT07297394Recruiting
How the immune system supports early pregnancy
This study looks at how the immune system helps the body accept a pregnancy. It involves blood samples from people who are pregnant or going through IVF/ICSI, or who have had a miscarriage.
BaselAges 18 years+ - NCT07744373Recruiting
Breast milk study for infant food tolerance
This study looks at cells and molecules in breast milk that may affect how babies develop tolerance to foods. If you are a mother exclusively breastfeeding and your baby is under 9 months old, you may be able to join.
IstanbulAges birth–9 months - NCT06478537RecruitingPhase 2
Hetrombopag for Immune Tolerance in ITP After Platelet Recovery
This study tests whether a drug called hetrombopag can help your immune system stop attacking your platelets, so your platelet count stays up even after stopping the drug. It's for people with ITP who responded well to hetrombopag but want to see if they can stay in remission without it.
Beijing, Beijing MunicipalityAges 18–50 - NCT04571203RecruitingPhase 1
Kidney transplant plus blood-cell treatment to help the graft settle
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
Palo Alto, CaliforniaAges 18–65 - NCT03591302RecruitingPhase 1
Stem cell transplant to stop anti-rejection drugs after kidney transplant
This study tries to use a stem cell transplant from your original kidney donor to help your body accept the kidney without needing lifelong anti-rejection drugs. You must have a perfectly matched sibling donor who is still available.
Palo Alto, CaliforniaAges 18 years+ - NCT06697665RecruitingEarly Phase 1
LM103 vaccine with PD-1 for advanced solid tumors
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
China, Tianjin MunicipalityAges 18–75 - NCT06864975RecruitingPhase 4
Different doses of ADVATE for immune tolerance in boys with hemophilia A and inhibitors
This trial tests how different doses and schedules of the factor VIII medicine ADVATE can train the immune system to accept factor VIII again in boys with hemophilia A who have developed inhibitors. The goal is to find a better way to help their bodies stop blocking the treatment.
Beijing, Beijing MunicipalityAges birth–18 years - NCT06864598Enrolling by invitation
New immune cells to help stem cell transplant success
This trial tests whether a special type of immune cell (called CD8 regulatory precursors) can help prevent the body from rejecting a stem cell transplant from a donor. It is for patients receiving a stem cell transplant from a related donor.
Beijing, Beijing MunicipalityAges 18–60 - NCT05432362Recruiting
Energy sensing brain study in depression and weight groups
This study tests how the brain and body respond to “energy sensing” in people with depression and in people with different body weights. You may be asked to do assessments and follow specific health and diet rules so the researchers can compare groups.
Graz, StyriaAges 18–40 - NCT07660198RecruitingPhase 3
Pneumonia vaccine catch-up study for kids and teens
This trial tests a catch-up pneumococcal vaccine for children and adolescents who may have missed some doses. It aims to see how safe and effective the vaccine is in healthy kids aged 15 months to 17 years.
Birmingham, AlabamaAges 1.3 years–17 years - NCT06737224Recruiting
Fasting and exercise effects on immune health
This study looks at how a 48-hour fast, alone or combined with exercise, affects your immune system and blood sugar control. It may help explain how short-term fasting can improve health in active young adults.
Kelowna, British ColumbiaAges 19–35 - NCT07419243RecruitingPhase 1/Phase 2
Tolerance in milk and egg allergy in children
This study watches how milk and egg allergies change naturally over time or after oral immunotherapy (OIT) in children. It helps researchers understand how the immune system adapts, aiming to improve treatment for food allergies.
Madrid, MadridAges 4–17 - NCT07569029RecruitingPhase 1
HIV vaccine with treatment break to boost immune response
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
Birmingham, AlabamaAges 18–60 - NCT07095127RecruitingPhase 2
Testing NVG-2089 for immune thrombocytopenia
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
Greenville, North CarolinaAges 18–80 - NCT03955445RecruitingPhase 3
Study for long-term iptacopan in C3G or IC-MPGN
This Phase 3 trial looks at how well and how safely iptacopan works over the long term for people with C3G or IC-MPGN. You may be able to join if you already finished a specific earlier study and you’re currently healthy enough for long-term treatment.
Aurora, ColoradoAges 12–100 - NCT07104565RecruitingPhase 2
Tafasitamab for autoimmune blood cell disorders
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Glendale, ArizonaAges 18 years+ - NCT07421167RecruitingPhase 2
Ianalumab with TPO-RA for immune thrombocytopenia
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
Stamford, ConnecticutAges 18 years+ - NCT05141474RecruitingEarly Phase 1
Personalized immune cell treatment for advanced cancers after failed therapy
This trial tests a personalized therapy made from your own immune cells (TIL) picked to match your tumor’s “neoantigens,” plus standard immune-boosting medicine (including IL-2). It’s for people with advanced epithelial or immune “resistant” solid tumors whose cancer has continued growing despite available treatments.
BarcelonaAges 18 years+ - NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT06839456RecruitingPhase 1/Phase 2
Stem cell addback to prevent infections after transplant
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Philadelphia, PennsylvaniaAges 1 month–25 years
Hear when a new Immune Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Immune Tolerance trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for immune tolerance?
- Yes. Clin2 currently lists 21 recruiting immune tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.